News

News Subscription

Sep 30. 2019
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
Read more
Download
Aug 27. 2019
Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer
Read more
Download
Aug 20. 2019
Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
Read more
Download
Aug 13. 2019
Basilea starts phase 1/2 study with derazantinib in urothelial cancer
Read more
Download
Aug 06. 2019
Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)
Read more
Download
Jul 01. 2019
Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
Read more
Download
Jun 03. 2019
Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting
Read more
Download
May 02. 2019
Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada
Read more
Download
Apr 12. 2019
Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more
Download
Apr 10. 2019
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
Read more
Download